57 results about "Weissella" patented technology

The invention discloses a Weissella cibaria X1 strain with functions of regulating metabolism and reducing uric acid and an application of the Weissella cibaria X1 strain. 49 lactic acid bacteria are screened from samples of fermented vegetables, healthy human body oral cavities and piglet feces, and 10 lactic acid bacteria are screened through PCA analysis on the basis of metabolism regulation and obesity inhibition ability; the method comprises the following steps: carrying out safety evaluation and uric acid reduction capability evaluation on 10 strains, finally screening out a strain X1, and identifying that the strain X1 is Weissella cibaria; the X1 strain and metabolites thereof have the function of reducing uric acid, excretion of uric acid can be promoted by adjusting expression levels of OAT1, UOX and HNF4A in vivo, expression of HPRT is adjusted to prevent excessive generation of uric acid and further reduce the level of uric acid, and a new way is provided for developing a uric acid reducing method without side effects.

The invention belongs to the technical field of aquaculture, and particularly relates to a pearl grouper fry rearing method. According to the method, firstly, after the roes are hatched, the fries are soaked with a bactericide, harmful bacteria on the surfaces of the roes and in a hatching pond can be effectively killed, and a bacteria solution of lactobacillus brevis serves as the bactericide, so that the use of antibiotics is reduced while the growth of pathogenic bacteria is inhibited; the culture pond is divided into 1m * 1m spaces by the partition plates, so that the phenomenon that the fries kill each other or snatch for food due to insufficient spaces is avoided, and uniform growth of the fries is facilitated; culture is carried out in stages according to nutritional requirements of different growth stages, and the Weissella microbial inoculum and the lactococcus lactis microbial inoculum are added to the feed in each stage, so that the intestinal microecological balance of the fry is adjusted, the growth and reproduction of harmful bacteria are inhibited, the intestinal digestion and absorption functions of the fry are enhanced, and the utilization rate of the feed is increased.

The invention discloses a Weissella virida 38-3 strain and an application thereof. Relates to the technical field of microorganisms. The invention provides a strain and application thereof. The strain is safe in separation source, high in growth speed and excellent in fermentation performance; the strain has the advantages of good biological safety, no hemolytic activity and no generation of bioamine, is sensitive to antibiotics such as ampicillin, erythromycin, kanamycin, streptomycin, tetracycline, vancomycin, chloramphenicol, gentamicin, clindamycin, ciprofloxacin, cefixime and the like, has good probiotic performance, has good gastric juice and intestinal juice tolerance and strong cell surface adhesion, and can be used for preparing antibiotics. Good pathogenic bacterium inhibiting and cholesterol lowering capabilities are realized. The strain disclosed by the invention can be used as a probiotic to prepare a food leavening agent, multifunctional medicines, functional foods or health-care foods, and has wide market prospects and application values.

The invention provides a culture method of Weissella fusiformis RM125 and application of the Weissella fusiformis RM125 in mandarin fish culture, a probiotic strain is named as Weissella fusiformis RM125, is identified as Weissella, is preserved in China General Microbiological Culture Collection Center on November 11, 2024, and has a preservation number of CGMCC NO.32556. The invention further provides a preparation method of the Weissella fusiformis RM125. The strain can be stably planted in the intestinal tract of the feed siniperca chuatsi, can significantly improve the intestinal tract health of the siniperca chuatsi, significantly promotes the growth of the siniperca chuatsi, and reduces

The invention discloses a bacteriostatic Weissella fusiformis LCOR4 strain and an application of the bacteriostatic Weissella fusiformis LCOR4 strain. The bacteriostatic Weissella fusiformis LCOR4 strain is separated from marine sludge in an intertidal zone of a mangrove forest area and is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC NO: 64982. The LCOR4 strain can effectively inhibit the growth of aquatic animal pathogenic bacteria such as vibrio anguillarum, vibrio harveyi, vibrio parahaemolyticus, aeromonas hydrophila and edwardsiella tarda, and can be prepared into an antibacterial agent or a microbial preparation, and the antibacterial activity of the LCOR4 strain is utilized to prevent and treat diseases caused by pathogenic bacteria infection. Besides, the LCOR4 strain is insensitive to antibacterial drugs such as enrofloxacin, neomycin, norfloxacin and rifampicin, and the strain can be combined with the insensitive or drug-resistant antibacterial drugs, so that the antibacterial effect is enhanced, diseases caused by pathogenic bacterium infection are better prevented and treated, and the long-term, stable and healthy development of the aquaculture industry is facilitated.

The invention relates to the technical field of probiotic development and utilization, in particular to a goose source Weissella cibaria F11 and application thereof. The Weissella cibarius F11 is preserved in the China General Microbiological Culture Collection Center on July 11, 2025, and the preservation number is CGMCC NO.35211. The Weissella cibarius F11 has the characteristics of good acid resistance and cholate resistance, and can be used for preparing the acid-resistant and cholate-resistant strain. And the bacillus subtilis has a good inhibition effect on pathogenic bacteria such as escherichia coli, pseudomonas aeruginosa, staphylococcus aureus and salmonella typhimurium, and also has stable acid production capacity and good safety. The Weissella sinus F11 provided by the invention meets the probiotic characteristic standard, the antibiotic resistance spectrum of the Weissella sinus F11 meets the feed probiotic safety standard, the growth of goslings can be remarkably promoted, the death rate and diarrhea occurrence rate of the goslings can be remarkably reduced, and the weissella sinus F11 can be used for preparing feed probiotics. The development potential in the fields of preparation of bacteriostatic and antibacterial drugs, probiotics for poultry feed, feed additives, poultry feed and the like is huge.

The invention belongs to the technical field of biological medicines, and discloses application of Weissella cibaria ZMC030 and exopolysaccharides thereof in prevention and treatment of colitis. The preservation number of the Weissella sinus ZMC030 is CCTCC (China Center for Type Culture Collection) NO: M 20241261, and the Weissella sinus ZMC030 is preserved in the China Center for Type Culture Collection. The Weissella cibaria ZMC030 can secrete exopolysaccharide, and the secreted exopolysaccharide can relieve intestinal injury, reduce apoptosis of intestinal epithelial cells, effectively protect intestinal mucosa barriers and reduce the inflammation level; moreover, intestinal microorganisms and metabolites thereof can be regulated and controlled, the level of pro-inflammatory microorganisms is reduced, the level of anti-inflammatory microorganisms and short-chain fatty acid is increased, and ulcerative colitis symptoms of mice are finally relieved; in addition, the exopolysaccharide has no influence on the weight and the growth state of the mouse, has no damage to important visceral organs, and is high in safety. Therefore, the Weissella cibaria ZMC030 and the exopolysaccharide secreted by the Weissella cibaria ZMC030 can be used for preparing the medicine for relieving or / and treating the colitis.

Weissella confusa WSG1 with digestion-assisting capacity is provided. The bacterial strain was preserved in the China General Microbiological Culture Collection Center (CGMCC) on Jun. 11, 2021 with a preservation number of CGMCC NO. 22697 and a nucleotide sequence shown in SEQ ID NO: 1. The bacterial strain of the present invention overcomes the problem of poor treatment effect of antibiotics and other medicaments in the prior art, has good safety, can survive in the gastrointestinal environment, has good susceptibility to antibiotics, has a remarkable inhibitory effect on common diarrhea-causing pathogenic bacteria, has digestion-assisting capacity, and is orally administered without toxicity. Therefore, a new available bacterial strain for the development of probiotics for maintaining the health capability of the intestinal tracts of canine organisms is provided herein.

The present invention discloses a strain of Enterobacteria mesenteroides MbWp‑25 and its products and applications. The Enterobacteria mesenteroides was deposited in the Guangdong Provincial Microbial Culture Collection Center on February 11, 2022, with a deposit number of GDMCC No: 62252. The Enterobacteria mesenteroides has good acid production ability and anti-bile salt effect, and thus also has good antibacterial properties, can inhibit pathogenic bacteria, promote host growth and development, and has extremely wide application value. Moreover, the bacteria also has an inflammatory treatment effect, and also has a good application effect in food fermentation. The freeze-dried powder product prepared by the bacteria is low in cost, high in storage survival rate, and simple in preparation process, and also has extremely high application value.

The invention relates to the technical field of microbial fermentation and food processing, and particularly discloses Weissella fusiformis JMF-006 as well as a mutagenesis method and application thereof. The invention provides a Weissella fusiformis JMF-006 with the exopolysaccharide yield of 20-25g / L. The Weissella fusiformis JMF-006 is obtained by breeding through a mutation breeding method of a high-yield EPS strain, and the mutation breeding method can also be used for culturing other high-yield EPS strains. The invention provides a strain composition, the strain composition comprises Weissella fusiformis JMF-006 or a high-yield EPS strain, other lactic acid bacteria strains (such as lactobacillus plantarum JMF-001 and lactobacillus casei JMF-002) can be further compounded, and the obtained strain composition has more excellent fermentation performance. When the Weissella fusiformis JMF-006, the high-yield EPS strain and the strain composition provided by the invention are applied to the fermentation process of food-derived drinks, a fermented product with stable properties and better flavor can be obtained, and the technical problems that the yield of extracellular polymeric substances is low, the fermentation performance is poor and the application range is narrow in an existing lactic acid bacteria starter are solved.

The invention relates to the technical field of microorganisms, in particular to Weissella fusiformis JWC120 with a function of inhibiting common harmful bacteria in animal breeding and application of the Weissella fusiformis JWC120. The Weissella fusiformis JWC120 with the function of inhibiting common harmful bacteria in animal breeding, provided by the invention, has the preservation number of CGMCC No.31945, and can effectively inhibit common escherichia coli, salmonella, staphylococcus aureus and shigella in animal breeding; a bacteriocin crude extract of the strain has a remarkable inhibition effect on common staphylococcus aureus in animal breeding, and has a good application prospect in animal disease prevention and treatment and development of livestock and poultry breeding health-care products.

This invention belongs to the field of microbial technology, specifically relating to a method for preparing and applying a fused Weissella extracellular polysaccharide. The extracellular polysaccharide of this invention is composed of glucose monosaccharide, and the glucose linkages include terminal glucose t-Glc(p), 1→4 linked glucose, 1→4,6 linked glucose, 1→3,6 linked glucose, and 1→2,6 linked glucose, with a relative molar ratio of (8~8.5):(1~1.2):(81~82):(7~7.5):(1~1.2):(0.5~1). It possesses excellent water-holding capacity, oil-holding capacity, emulsifying properties, and emulsion stability, and can be used as a highly efficient moisturizer, emulsifier, emulsion stabilizer, cosmetic additive, pharmaceutical additive, and food additive, showing broad application prospects in the food, cosmetic, and pharmaceutical fields.

The invention provides laminarin, a lentinus edodes stem polysaccharide hydrolysate and application of the laminarin and the lentinus edodes stem polysaccharide hydrolysate in promotion of Weissella proliferation, and belongs to the technical field of microorganisms. The method comprises the following steps: mixing kelp powder with water, extracting, concentrating, carrying out alcohol precipitation by using ethanol with the final concentration of 18-22% v / v, dissolving the precipitate in water, and dialyzing to obtain laminarin; the method comprises the following steps: mixing lentinus edodes stem powder with water, extracting, concentrating, carrying out alcohol precipitation by using ethanol with the final concentration of 18-22% v / v, carrying out alcohol precipitation by using ethanol with the final concentration of 48-52% v / v, removing protein, hydrolyzing by using a hydrochloric acid solution, and dialyzing to obtain the lentinus edodes stem polysaccharide hydrolysate. The laminarin and lentinus edodes stem polysaccharide hydrolysate prepared by the invention is beneficial to the growth and reproduction of Weissella and can be used for preparing a preparation for promoting the proliferation of Weissella.

The weissella cibarius is named as weissella cibarius H3 and is preserved in the Guangdong Microbial Culture Collection Center, the preservation number of the weissella cibarius H3 is GDMCC NO.65902, the preservation address of the weissella cibarius H3 is the 5th floor of the building 59, No. 100 courtyard, Xianlie Middle Road, Guangzhou, and the preservation date of the weissella cibarius H3 is February 18, 2025. The Weissella sinus producing bacteriocin disclosed by the invention can produce bacteriocin with broad-spectrum antibacterial activity, and the bacteriocin has an antibacterial effect on various food-borne gram-negative pathogenic bacteria (vibrio alginolyticus, vibrio parahaemolyticus and the like) and gram-positive bacteria (listeria monocytogenes, enterococcus faecalis and the like), and has application potential in the aspects of food preservation and fresh keeping.

This invention discloses *Wesleyanus esculenta* strain, its fermentation product filtrate, and its biological products, belonging to the field of cosmetic technology. This strain can be used in cosmetics, exhibiting excellent HAS inhibition ability and significant DPPH and ABTS free radical scavenging capabilities, achieving good antioxidant effects. Secondly, at various concentrations, its fermentation product filtrate can significantly downregulate the proportion of SA-β-Gal positive cells and significantly inhibit the gene expression of various matrix metalloproteinases, demonstrating a certain effect in reducing cellular aging markers. Furthermore, its fermentation product filtrate can inhibit tyrosinase activity in vitro and significantly inhibit melanin production in a zebrafish model, showing potential as a tyrosinase inhibitor or melanin production inhibitor. Its fermentation product filtrate can also significantly inhibit the secretion of the cellular inflammatory factor NO, exhibiting good soothing effects and a certain ability to regulate the skin microecology.

The invention discloses Weissella sinus PD13 for improving Alzheimer's disease and application of the Weissella sinus PD13, and relates to the technical field of biological medicine. Experiments prove that Weissella cibaria PD13 can improve spatial learning and memory impairment and autonomous exploration ability of AD model mice in Alzheimer's disease model mice induced by brain injection of A beta oligomer, and alleviate damage of neurons in hippocampal regions of the Alzheimer's disease model mice, so that the effect of protecting neurons is achieved, and the Weissella cibaria PD13 can be used for preparing drugs for treating Alzheimer's disease. According to the present invention, the Weissella cibaricola can effectively prevent and treat the Alzheimer's disease, increase the glutathione content and the superoxide dismutase enzyme activity of the mouse serum, and reduce the malondialdehyde content, such that the Weissella cibaricola has good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.

The invention provides a compound micro-ecological preparation prepared from chitosan oligosaccharide and application of the compound micro-ecological preparation. The compound micro-ecological preparation is prepared from the chitosan oligosaccharide and Weissella sinus, and the preservation number of the Weissella sinus is CGMCC (China General Microbiological Culture Collection Center) NO.32640. Bacterial colony composition analysis shows that after the compound micro-ecological preparation is added into the feed, intestinal tracts of the soft-shelled turtles are enriched with bacteria beneficial to conversion of nutrient substances, and flora balance is maintained; immune enzyme activity analysis results prove that T-AOC activity, CAT activity, GSH-Px and SOD activity in soft-shelled turtle bodies can be improved by adding the compound micro-ecological preparation into the feed, ACP and MDA enzyme activity is reduced, and oxidation resistance and antibacterial ability of the soft-shelled turtles are improved; meanwhile, the compound micro-ecological preparation is added, so that the intestinal digestive enzyme activity can be improved, the amino acid content in soft-shelled turtle muscles is increased, and the growth of the soft-shelled turtles is promoted.

The invention relates to the technical field of microorganisms, and particularly discloses a Weissella fusiformis HTD7 and application thereof. The preservation number of the Weissella fusiformis HTD7 is CGMCC No.29775, the Weissella fusiformis HTD7 is good in antibacterial effect and different in color under different pH values, when the Weissella fusiformis HTD7 is applied to fermentation of high-fiber matrix cereals, the content of various beneficial components in a fermentation product can be increased, the product effect can be improved, when the Weissella fusiformis HTD7 is applied to preparation of bread and steamed buns, the product quality can be improved, and the Weissella fusiformis HTD7 can also be used as an edible dye, so that the Weissella fusiformis HTD7 can be used for The method can be widely applied to food preparation.

The application discloses a low-temperature rotting-promoting composite microbial inoculum, a high-efficiency in-situ straw returning method and application, and belongs to the technical field of microbial inoculums. The low-temperature rotting-promoting composite microbial inoculum comprises Stenotrophomonas maltophilia JGDQ29-2, Bacillus JX-7, Weissella covesi zqw90, Weissella paramesenteroides zqw26 and Neurospora crassa N7, and the mass ratio of the viable bacterial numbers of the Stenotrophomonas maltophilia JGDQ29-2, the Bacillus JX-7, the Weissella covesi zqw90, the Weissella paramesenteroides zqw26 and the Neurospora crassa N7 is 1-2:1-2:1-2:1.5-2:2.5-3. The application realizes the synchronous high-efficiency degradation of each component of the straw, improves the overall rotting efficiency and improves the soil nutrient components by screening high-efficiency cellulose, hemicellulose and lignin degradation strains and constructing a composite microbial system with multiple bacteria symbiosis and function complementation.

Disclosed are universal LAB test kits, assays, apparatus and compositions for detecting and quantifying Lactobacillus, Pediococcus and Weissella bacteria, or combinations thereof that contaminate biological materials such as fermentation mashes for production of ethanol from a crop such as corn. The assays can be performed on-site by ethanol technicians having limited laboratory experience and are based on quantitative PCR (qPCR) methods. Primers and probes are described that specifically hybridize to a LAB bacteria gene. Also disclosed are sample preparation methods and apparatus, including a filtration syringe (100) that can increase sensitivity of the assays up to about 1000-fold compared to traditional sample preparation methods.

The present invention discloses a strain of Weissella confusa and its application in producing neuromodulators. The strain is called Weissella confusa W1h, and the deposit number is CGMCC NO.25725. The strain was deposited at the General Microbiology Center of China National Committee for the Preservation and Administration of Microorganisms at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing on September 15, 2022. Weissella confusa W1h in the present invention can secrete neuromodulators such as tryptophan, dopamine, short-chain fatty acids, etc., which can be used for the development and utilization of antidepressant probiotic products, and the strain has good tolerance to the gastrointestinal environment, has high intestinal adhesion and antibacterial activity, and can be used to improve the structure of intestinal microbial flora and inhibit the growth and reproduction of pathogenic bacteria.

The invention discloses Weissella sinus PD13 and application thereof in preparation of a product for treating or relieving Parkinson's disease, and belongs to the technical field of biological medicine. The Weissella sinus PD13 is preserved in the Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC No.65891. The Weissella sinus PD13 has the advantages that the Weissella Experiments prove that the Weissella sinus PD13 can be used for reducing the aggregation of alpha-Syn on the body wall of the PD model nematode NL5901; the movement ability of the NL5901 nematode is improved; the service life of the NL5901 nematode is prolonged; the fat content in the NL5901 nematode body is increased; the invention also finds that the Weissella sinus PD13 can reduce the oxidative stress level in the NL5901 nematode body. The Weissella sinus PD13 provided by the invention has a good treatment or alleviation effect on the Parkinson's disease, and a new way is provided for developing related drugs for treating or alleviating the Parkinson's disease.

The invention belongs to the technical field of biological medicines, and relates to application of Weissella sinus ZMC030 and exopolysaccharides thereof in prevention and treatment of toxic and side effects caused by chemotherapeutic drugs. The invention discovers that the Weissella cibaria ZMC030 exopolysaccharide can prevent, relieve or / and treat toxic and side effects caused by chemotherapeutic drugs for the first time; wherein the toxic and side effects of the heart comprise heart injury, myocardial cell apoptosis, cardiac fibrosis, heart tissue inflammation and the like; the intestinal toxic and side effects comprise intestinal injury, intestinal tissue structure disorder or / and intestinal mucosal barrier disorder, intestinal mucosal barrier permeability increase and intestinal flora disorder. Therefore, the Weissella cibaricola ZMC030 and the exopolysaccharide secreted by the Weissella cibaricola ZMC030 can be used for preparing products for preventing, relieving or / and treating cardiac toxic and side effects and intestinal toxic and side effects caused by chemotherapy drugs.

The present invention belongs to the field of biomedicine technology, and discloses a fusion of Weissella J1-1 and its application. The fusion Weissella J1-1 is deposited with CCTCC NO: M 20232334 and is deposited in the China Center for Type Culture Collection. The fusion Weissella J1-1 can secrete exopolysaccharide, and the exopolysaccharide secreted can significantly improve the lung function of mice with pulmonary fibrosis. It was found by observing lung tissue sections that it can also significantly improve lung tissue fibrosis, has no effect on the weight and growth status of mice, and has no damage to important organs, with high safety. In addition, cell experiments have found that exopolysaccharide can also significantly improve the expression of fibrosis-related genes in lung fibroblasts, and has no effect on the vitality of fibroblasts. Therefore, the present invention fusion Weissella J1-1 and the exopolysaccharide secreted by it can be used to prepare a drug for alleviating or / and treating pulmonary fibrosis.

The invention relates to a Weissella confusa strain, which is classified and named as Weissella confusa SY628, is preserved in China General Microbiological Culture Collection Center (CGMCC) on September 19, 2024, and has a preservation number of CGMCC No.32006. The Weissella confusa strain is named as Weissella confusa SY628, and the Weissella confusa strain is named as Weissella confusa SY628. The invention further discloses a microbial agent, a biological agent, a purification screening method and application of the fused Weissella. The fused Weissella SY628 disclosed by the invention is a lactic acid bacterium capable of producing exopolysaccharides at high yield, has better acid resistance and cholate resistance, has a good escherichia coli inhibition effect, is safe to eat, and can be used for remarkably improving the solidification effect of sour soybean milk.

The present invention relates to strains and compositions. The present invention provides a bacterial strain having at least 95% genetic homology with one or more bacterial strains selected from the group consisting of: Lactobacillus plantarum LB356R, preserved at DSM 33094; the invention relates to lactobacillus plantarum LB244R, which is preserved by DSM 32996. The invention discloses lactobacillus plantarum LB316R, which is preserved in DSM 33091. The lactobacillus plantarum LB312R is preserved in the form of DSM 33098; the lactobacillus casei LB113R is preserved in the form of DSM 32907; the lactobacillus casei LB116R is preserved in the form of DSM 32908, and the lactobacillus casei LB116R is preserved in the The enterococcus faecium LB276R is preserved in the form of DSM 32997; the leuconostoc mesenteroides LB349R is preserved in the form of DSM 33093; the invention relates to Weissella virida LB10G, which is preserved in the form of DSM 32906. The invention also provides compositions comprising the one or more bacterial strains.

The invention discloses Weissella virida and application of Weissella virida in the aspects of hangover alleviating, inflammation resisting, aging resisting, lipid lowering and liver protecting. According to the invention, a Weissella viridescens strain is obtained through screening, the Weissella viridescens strain is named as Weissella viridescens NP12, and the Weissella viridescens strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on October 23, 2025 in No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.36310. The Weissella viridescens strain is named as Weissella viridescens strain is named as Weissella viridescens. The strain NP12 has multiple effects of dispelling the effects of alcohol, reducing lipid, protecting the liver, resisting inflammation, resisting aging, regulating intestinal flora and the like, and can also be used for fermenting medicinal and edible traditional Chinese medicinal materials such as radix puerariae, and the total polyphenol content, the anti-inflammation activity, the anti-aging activity and the liver protection activity of an obtained fermentation product are obviously superior to those of unfermented radix puerariae, so that the strain NP12 or the fermentation product thereof can be used for developing multifunctional foods or medicines.

The invention provides Weissella cibaria, a Weissella cibaria and mulberry leaf co-fermentation product and application of the Weissella cibaria and mulberry leaf co-fermentation product in sugar and lipid reduction. The Weissella sinus (Weissella sp.) BYQ07 obtained through separation is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36500, and the preservation date is November 4, 2025. The Weissella sinus (Weissella sp.) BYQ07 has the advantages that the Weissella sinus (Weissella sp. The bacterium has various potential biological functions and metabolic pathways, such as carbon metabolism, nitrogen metabolism, energy generation and conversion and the like. The invention further provides a weissella cibaria BYQ07 and mulberry leaf co-fermented product, and the weissella cibaria BYQ07 and mulberry leaf co-fermented product is obtained by co-fermenting weissella cibaria BYQ07 and mulberry leaves. Researches discover that Weissella cibaria BYQ07 and a co-fermentation product of Weissella cibaria BYQ07 and mulberry leaves have obvious effects in the aspects of reducing blood sugar, reducing fat deposition, improving insulin resistance, improving liver functions, relieving liver fatty degeneration and the like, so that the Weissella cibaria BYQ07 has obvious effects in the aspect of developing products for reducing blood sugar, reducing blood fat, improving insulin resistance and improving liver functions. The important application value is realized.

The invention discloses an application of a response marker for treating ulcerative colitis by coprophilous fungi transplantation, and belongs to the technical field of biology, as a further optimization scheme of the invention, the coprophilous fungi comprise Streptococcus, Faecalibacteria, Weissella, Lactococcus and Rombout, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation has the advantages that the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized. As a further optimization scheme of the invention, the coprophilous bacteria further comprise Streptococcus pluviae, Bifidobacterium longum, Lactococcus garviae, Weissella parasites, Lactococcus fermentum and Lactococcus lactis, and the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae and the In the invention, the flora change before and after coprophilous fungus transplantation treatment is researched on a patient with ulcerative colitis, a series of specific coprophilous fungus varieties are identified, and the effect of the strains in UC treatment is not confirmed in the previous research. Through quantitative analysis of existence and abundance of the specific strains, response conditions of UC patients to FMT treatment are predicted.

Aiming at the current situation that probiotics are used for treating periodontitis in the prior art, the invention provides a strain of mixed Weissella confusa LHJY. The mixed Weissella confusa is named as a mixed Weissella confusa LHJY strain, and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 20251930, and the preservation date is September 1, 2025. The method comprises the following steps: separating and purifying a pickled vegetable sample by an inventor to obtain probiotic mixed Weissella LHJY; a bacteriostatic experiment and a biological membrane removal experiment detect that the confused Weissella sp. LHJY has a remarkable inhibition effect on important periodontal pathogenic bacteria, namely porphyromonas gingivalis (P. gingivalis) and fusobacterium nucleatum (F. nucleatum), and fills up the blank of application of the confused Weissella sp. To treatment of periodontitis in the prior art, and the confused Weissella sp. LHJY has a remarkable inhibition effect on the periodontal pathogenic bacteria, namely porphyromonas gingivalis (P. gingivalis) and fusobacterium nucleatum (F. nucleatum). Moreover, the confused Weissella sp. LHJY can tolerate lysozyme with a relatively high concentration, effectively reduces the expression of inflammatory factors including interleukin 1 beta, tumor necrosis factor alpha and interleukin 6 in an inflammatory cell model, and has an important application prospect in the aspects of inhibiting periodontal disease pathogenic bacteria and regulating immune response.